Literature DB >> 10230645

Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene.

A W Thorburn1, M E Baldwin, G Rosella, J D Zajac, S Fabris, S Song, J Proietto.   

Abstract

AIMS/HYPOTHESIS: Obesity, glucose intolerance, dyslipidaemia and hypertension are a cluster of disorders (syndrome X) affecting many people. It has been hypothesised that these abnormalities are caused by insulin resistance, but definitive proof is lacking. We have developed transgenic rats in which the rate-limiting gluconeogenic enzyme, phosphoenolpyruvate carboxykinase, is non-insulin responsive. The aim of our study was to investigate whether syndrome X develops in these animals and if a high-fat diet interacts with this genetic defect.
METHODS: Chow-fed transgenic and control rats aged 1, 3, 6 and 17 months and a subgroup of transgenic and control rats fed chow plus cafeteria foods for 6 months were examined for features of syndrome X.
RESULTS: At 3 months, transgenic rats had fasting and postprandial hyperinsulinaemia, mild obesity (in abdominal and, to a lesser extent, peripheral regions) and fasting hypercholesterolaemia. Hypertriglyceridaemia was evident after 6 months while hyperglycaemia was apparent at 17 months. Hypertension had not developed by 17 months. The effect of a high-fat diet on insulin, glucose, body weight and body fat was more dramatic than the effect of the transgene alone while the effect of a high-fat diet on cholesterol and triglyceride was similar to the transgene. This illustrates that a high-fat diet is a potent catalyst for many abnormalities associated with syndrome X. There was no evidence of an additive effect of the high-fat diet plus transgene. CONCLUSION/
INTERPRETATION: Therefore rats genetically-engineered with a non-insulin responsive gluconeogenic enzyme develop several aspects of syndrome X, supporting the hypothesis that insulin resistance initiates this cluster of disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230645     DOI: 10.1007/s001250051174

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  5 in total

1.  Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.

Authors:  Elango Kathirvel; Kengathevy Morgan; Ganesh Nandgiri; Brian C Sandoval; Marie A Caudill; Teodoro Bottiglieri; Samuel W French; Timothy R Morgan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

Review 2.  Measurement of insulin resistance in vivo.

Authors:  S Del Prato
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney.

Authors:  B J Lamont; S Andrikopoulos; A Funkat; J Favaloro; J M Ye; E W Kraegen; K F Howlett; J D Zajac; J Proietto
Journal:  Diabetologia       Date:  2003-07-29       Impact factor: 10.122

4.  Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance.

Authors:  T Ferre; E Riu; S Franckhauser; J Agudo; F Bosch
Journal:  Diabetologia       Date:  2003-11-12       Impact factor: 10.122

Review 5.  Overview of animal models of obesity.

Authors:  Thomas A Lutz; Stephen C Woods
Journal:  Curr Protoc Pharmacol       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.